Share on LinkedInShare on LinkedIn

ARTICLE · 24 AUGUST 2017

Federal Circuit Provides More Guidance On Biosimilar Patent Litigation

The Federal Circuit first addressed Hospira's argument that the Federal Circuit lacked jurisdiction to review the district court's interlocutory order.

United StatesIntellectual Property

In Amgen Inc. v. Hospira, Inc., the Federal Circuit held that Amgen could not obtain discovery related to activities that might infringe a patent that it had not asserted in its biosimilar patent litigation against Hospira. In particular, the court held that it lacked jurisdiction—under the collateral order doctrine—over the district court's denial of Amgen's motion to compel discovery regarding the cell-culture medium Hospira uses to make its biosimilar product. The court also held that Amgen had failed to show its "clear and indisputable'" right to the information as required for a writ of mandamus.


Any opinions expressed in this article are personal to the authors and do not reflect the views of Foley & Lardner LLP, its partners, or its clients.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from